Relationship between bone marrow angiogenesis and plasma cell infiltration and serum β2-microglobulin levels in patients with multiple myeloma

2001 ◽  
Vol 80 (10) ◽  
pp. 598-601 ◽  
Author(s):  
Sezer O. ◽  
Niemöller K. ◽  
Jakob C. ◽  
Zavrski I. ◽  
Heider U. ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Plasma Cell ◽  
Cell Infiltration ◽  
Β2 Microglobulin ◽  
Plasma Cell Infiltration

BONE MARROW PLASMA CELL INFILTRATION IN MULTIPLE MYELOMA

1984 ◽  
Vol 57 (2) ◽  
pp. 351-352 ◽  
Author(s):  
Aimery De Gramon ◽  
Oscar Benitez ◽  
Nicole Smadja ◽  
Philippe Brissaud ◽  
Agnés Sirinelli ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Plasma Cell ◽  
Cell Infiltration ◽  
Plasma Cell Infiltration ◽  
Bone Marrow Plasma

Quantification of bone marrow plasma cell infiltration in multiple myeloma: usefulness of bone marrow aspirate clot with CD138 immunohistochemistry

2016 ◽  
Vol 35 (3) ◽  
pp. 323-328 ◽  
Author(s):  
Kosei Matsue ◽  
Yuya Matsue ◽  
Kaoru Kumata ◽  
Yoshiaki Usui ◽  
Yasuhito Suehara ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Plasma Cell ◽  
Bone Marrow Aspirate ◽  
Cell Infiltration ◽  
Plasma Cell Infiltration ◽  
Bone Marrow Plasma

Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma

Blood ◽  
2005 ◽  
Vol 106 (9) ◽  
pp. 2977-2981 ◽  
Author(s):  
Paul Gerard Guy Richardson ◽  
Bart Barlogie ◽  
James Berenson ◽  
Seema Singhal ◽  
Sundar Jagannath ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Plasma Cell ◽  
Performance Status ◽  
Myeloma Cell ◽  
Tumor Burden ◽  
Cell Infiltration ◽  
Chromosome 13 ◽  
Β2 Microglobulin ◽  
Phase 2 Trial ◽  
Plasma Cell Infiltration

Abstract Bortezomib, a potent and reversible proteasome inhibitor, affects the myeloma cell and its microenvironment, resulting in down-regulation of growth and survival signaling pathways and durable responses in patients with relapsed and refractory myeloma. Potential associations between baseline parameters and outcomes with bortezomib were explored in 202 patients who received bortezomib 1.3 mg/m2 twice weekly for 2 weeks every 3 weeks for up to 8 cycles in a phase 2 trial. Using European Group for Blood and Marrow Transplantation criteria, the response rate (complete or partial response) to bortezomib alone was 27% and was not associated with sex, race, performance status, isotype, chromosome 13 deletion, number or type of previous therapies, or concentration of hemoglobin or β2-microglobulin. By multivariate analysis, factors associated with lower response were being age 65 or older versus younger than 65 (19% vs 32%; P < .05) and plasma-cell infiltration in bone marrow greater than 50% versus 50% or less (20% vs 35%; P < .05). Factors that may be indicative of tumor burden (bone marrow plasma-cell infiltration greater than 50%, hypoalbuminemia, thrombocytopenia) were predictive of overall survival. Chromosome 13 deletion and elevated β2-microglobulin, generally considered poor prognostic factors, were not predictive of poor outcome with bortezomib in this study.

BONE MARROW PLASMA CELL INFILTRATION IN MULTIPLE MYELOMA

1984 ◽  
Vol 57 (2) ◽  
pp. 352-353 ◽  
Author(s):  
M. Cavo ◽  
M. Baccarani ◽  
M. Gobbi ◽  
A. Lipizer ◽  
S. Tura
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Plasma Cell ◽  
Cell Infiltration ◽  
Plasma Cell Infiltration ◽  
Bone Marrow Plasma

scholarly journals Relationship between Circulating BAFF Serum Levels with Proliferating Markers in Patients with Multiple Myeloma

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Michael G. Alexandrakis ◽  
Parascevi Roussou ◽  
Constantina A. Pappa ◽  
Ippokratis Messaritakis ◽  
Athina Xekalou ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Growth Factor ◽  
Plasma Cell ◽  
Serum Levels ◽  
Cell Infiltration ◽  
Ki 67 ◽  
Myeloma Cells ◽  
Plasma Cell Infiltration ◽  
Bone Marrow Plasma

In multiple myeloma, there are many factors influencing the growth of the malignant clone in direct and indirect manners. BAFF is a growth factor for myeloma cells. The aim of the study was to measure its circulating levels in 54 pretreatment patients, along with serum levels of other proliferation markers, such as interleukins-6, -10, and -15, CRP, and beta-2 microglobulin, as well as bone marrow plasma cell infiltration and expression of Ki-67 PI, in various stages of the disease and after effective treatment in 28 of them. Serum levels of the previously mentioned factors were measured by ELISA, whereas bone marrow plasma cell infiltration and Ki-67 expression were estimated immunohistochemically. All measured parameters were higher in pretreated myeloma patients compared to healthy population and were also increasing with the progression of the disease. They all also decreased after effective therapy. Furthermore, all pretreatment values correlated to each other. BAFF seems to be an important growth factor for myeloma plasma cells. Measuring its serum levels, along with the previously mentioned cytokines, may provide important information regarding the degree of myeloma cells’ proliferation. Therefore, they all could be used as markers of proliferation and disease activity.

Comparison of plasma cell infiltration in bone marrow biopsies and aspirates in patients with multiple myeloma

1992 ◽  
Vol 82 (1) ◽  
pp. 46-49 ◽  
Author(s):  
W. E. Terpstra ◽  
H. M. Lokhorst ◽  
F. Blomjous ◽  
O. J. A. Th. Meuwissen ◽  
A. W. Dekker
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Plasma Cell ◽  
Cell Infiltration ◽  
Bone Marrow Biopsies ◽  
Plasma Cell Infiltration

scholarly journals Myelomatous Ascites and Pleural Effusion in Relapsed Multiple Myeloma

2021 ◽  
Author(s):  
Mizba Baksh ◽  
Ke Li ◽  
Liuyan Jiang ◽  
Victoria Alegria ◽  
Taimur Sher ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Pleural Effusion ◽  
Plasma Cell ◽  
Cell Infiltration ◽  
Aggressive Disease ◽  
Plasma Cell Infiltration ◽  
Fluid Cytology

Extramedullary multiple myeloma is seen in advanced and aggressive disease and occurs due to plasma cell infiltration of sites other than the bone marrow. Myelomatous ascites or pleural effusion is seen in less than 1 % of cases and can be differentiated from infectious etiologies based on fluid cytology.

Renal failure caused by plasma cell infiltration in multiple myeloma

2011 ◽  
Vol 15 (4) ◽  
pp. 586-590 ◽  
Author(s):  
Shiho Hanawa ◽  
Tetsu Akimoto ◽  
Eisuke Uehara ◽  
Makoto Inoue ◽  
Toshimi Imai ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Renal Failure ◽  
Plasma Cell ◽  
Cell Infiltration ◽  
Plasma Cell Infiltration
Sign in / Sign up

Export Citation Format

Share Document